Canopy Growth Corp vs SOLAI Limited — how do they compare? Canopy Growth Corp trades at $0.96 (market cap $398.46M), while SOLAI Limited trades at $3.14 (market cap $14.09M). The key difference: Canopy Growth Corp is far larger — about 28.3× SOLAI Limited's market cap. Which is the better fit depends on your goals.
| CGC | SLAI | |
|---|---|---|
Market Cap | $398.46M | $14.09M |
Sector | Health | Technology |
52-Week High | $1.92 | $30.66 |
52-Week Low | $0.86 | $2.74 |
Enterprise Value | $337.90M | $13.72M |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.
The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.
SLAI trades at $3.24, down 2.99% today, with a bullish technical signal supported by moving averages. The company shows concerning fundamentals with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Recent developments include the acquisition of a 51% stake in NEURALAND and the launch of Solode Neo AI device. The stock faces NYSE listing standard concerns but shows improved revenue guidance for 2026.
The outlook remains challenged by persistent losses and regulatory risks, though recent acquisitions and product launches offer potential growth catalysts. Investors face significant execution risk amid negative profitability metrics, while technical indicators suggest near-term price support around $3 with resistance at $4.
Trailing returns across standard periods
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →